<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260555</url>
  </required_header>
  <id_info>
    <org_study_id>DW1601-301</org_study_id>
    <nct_id>NCT04260555</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012 for Acute Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III
      Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012
      for Acute Bronchitis
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchitis Severity Score(BSS)</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Acute Bronchitis</condition>
  <arm_group>
    <arm_group_label>TEST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tid PO, DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tid PO, Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tid PO, Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1601</intervention_name>
    <description>Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)</description>
    <arm_group_label>TEST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW16011</intervention_name>
    <description>Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)</description>
    <arm_group_label>Reference 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW16012</intervention_name>
    <description>Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)</description>
    <arm_group_label>Reference 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both gender, 19 years ≤ age ≤ 80 years

          -  Bronchitis Severity Score* ≥ 5point at Visit 2 (Randomized Visit)

          -  Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)

          -  Those who can comply with the requirements of clinical trials

          -  Written consent voluntarily to participate in this clinical trial

        Exclusion Criteria:

          -  Patients who investigators determines to severe respiratory disease that would
             interfere with study assessment

          -  Patients with systemic infections requiring systemic antibiotic therapy

          -  patient with hemostatic disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

